Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Challenges in the search for an HIV vaccine.
Lemckert AA, Goudsmit J, Barouch DH. Lemckert AA, et al. Eur J Epidemiol. 2004;19(6):513-6. doi: 10.1023/b:ejep.0000032423.87658.68. Eur J Epidemiol. 2004. PMID: 15330122 Review.
Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells.
Havenga M, Vogels R, Zuijdgeest D, Radosevic K, Mueller S, Sieuwerts M, Weichold F, Damen I, Kaspers J, Lemckert A, van Meerendonk M, van der Vlugt R, Holterman L, Hone D, Skeiky Y, Mintardjo R, Gillissen G, Barouch D, Sadoff J, Goudsmit J. Havenga M, et al. J Gen Virol. 2006 Aug;87(Pt 8):2135-2143. doi: 10.1099/vir.0.81956-0. J Gen Virol. 2006. PMID: 16847108
Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein.
Sumida SM, Truitt DM, Lemckert AA, Vogels R, Custers JH, Addo MM, Lockman S, Peter T, Peyerl FW, Kishko MG, Jackson SS, Gorgone DA, Lifton MA, Essex M, Walker BD, Goudsmit J, Havenga MJ, Barouch DH. Sumida SM, et al. Among authors: lemckert aa. J Immunol. 2005 Jun 1;174(11):7179-85. doi: 10.4049/jimmunol.174.11.7179. J Immunol. 2005. PMID: 15905562
Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity.
Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, de Béthune MP, Kostense S, Penders G, Helmus N, Koudstaal W, Cecchini M, Wetterwald A, Sprangers M, Lemckert A, Ophorst O, Koel B, van Meerendonk M, Quax P, Panitti L, Grimbergen J, Bout A, Goudsmit J, Havenga M. Vogels R, et al. J Virol. 2003 Aug;77(15):8263-71. doi: 10.1128/jvi.77.15.8263-8271.2003. J Virol. 2003. PMID: 12857895 Free PMC article.
Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5.
Holterman L, Vogels R, van der Vlugt R, Sieuwerts M, Grimbergen J, Kaspers J, Geelen E, van der Helm E, Lemckert A, Gillissen G, Verhaagh S, Custers J, Zuijdgeest D, Berkhout B, Bakker M, Quax P, Goudsmit J, Havenga M. Holterman L, et al. J Virol. 2004 Dec;78(23):13207-15. doi: 10.1128/JVI.78.23.13207-13215.2004. J Virol. 2004. PMID: 15542673 Free PMC article.
31 results